Your browser doesn't support javascript.
loading
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta.
Stockley, Martin L; Ferdinand, Amanda; Benedetti, Giovanni; Blencowe, Peter; Boyd, Susan M; Calder, Mat; Charles, Mark D; Edwardes, Lucy V; Ekwuru, Tennyson; Finch, Harry; Galbiati, Alessandro; Geo, Lerin; Grande, Diego; Grinkevich, Vera; Holliday, Nicholas D; Krajewski, Wojciech W; MacDonald, Ellen; Majithiya, Jayesh B; McCarron, Hollie; McWhirter, Claire L; Patel, Viral; Pedder, Chris; Rajendra, Eeson; Ranzani, Marco; Rigoreau, Laurent J M; Robinson, Helen M R; Schaedler, Theresia; Sirina, Julija; Smith, Graeme C M; Swarbrick, Martin E; Turnbull, Andrew P; Willis, Simon; Heald, Robert A.
Afiliación
  • Stockley ML; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Ferdinand A; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Benedetti G; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Blencowe P; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Boyd SM; CompChem Solutions Ltd, St John's Innovation Centre, Cowley Rd, CambridgeCB4 0WS, U. K.
  • Calder M; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Charles MD; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Edwardes LV; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Ekwuru T; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Finch H; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Galbiati A; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Geo L; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Grande D; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Grinkevich V; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Holliday ND; Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K.
  • Krajewski WW; Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K.
  • MacDonald E; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Majithiya JB; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • McCarron H; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • McWhirter CL; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Patel V; Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K.
  • Pedder C; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Rajendra E; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Ranzani M; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Rigoreau LJM; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Robinson HMR; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Schaedler T; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Sirina J; Excellerate Bioscience Ltd., BioCity, Pennyfoot Street, NottinghamNG1 1GF, U. K.
  • Smith GCM; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
  • Swarbrick ME; Cancer Research Horizons Therapeutic Innovation, Jonas Webb Building, Babraham Research Campus, CambridgeCB22 3AT, U. K.
  • Turnbull AP; Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K.
  • Willis S; Cancer Research Horizons Therapeutic Innovation, The Francis Crick Institute, 1 Midland Road, LondonNW1 1AT, U. K.
  • Heald RA; Artios Pharma Ltd., B940, Babraham Research Campus, CambridgeCB22 3FH, U. K.
J Med Chem ; 65(20): 13879-13891, 2022 10 27.
Article en En | MEDLINE | ID: mdl-36200480
ABSTRACT
Human DNA polymerase theta (Polθ), which is essential for microhomology-mediated DNA double strand break repair, has been proposed as an attractive target for the treatment of BRCA deficient and other DNA repair pathway defective cancers. As previously reported, we recently identified the first selective small molecule Polθ in vitro probe, 22 (ART558), which recapitulates the phenotype of Polθ loss, and in vivo probe, 43 (ART812), which is efficacious in a model of PARP inhibitor resistant TNBC in vivo. Here we describe the discovery, biochemical and biophysical characterization of these probes including small molecule ligand co-crystal structures with Polθ. The crystallographic data provides a basis for understanding the unique mechanism of inhibition of these compounds which is dependent on stabilization of a "closed" enzyme conformation. Additionally, the structural biology platform provided a basis for rational optimization based primarily on reduced ligand conformational flexibility.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Reparación del ADN por Unión de Extremidades / Inhibidores de Poli(ADP-Ribosa) Polimerasas Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Reparación del ADN por Unión de Extremidades / Inhibidores de Poli(ADP-Ribosa) Polimerasas Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article